Drug Approval | July 10, 2023
Astellas receives FDA priority review for Zolbetuximab biologics license application
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
PEEK brings a new quality to dental care for patients
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Subscribe To Our Newsletter & Stay Updated
